[go: up one dir, main page]

AR049177A1 - Polipeptidos y conjugados de interferon-alfa - Google Patents

Polipeptidos y conjugados de interferon-alfa

Info

Publication number
AR049177A1
AR049177A1 ARP050102059A ARP050102059A AR049177A1 AR 049177 A1 AR049177 A1 AR 049177A1 AR P050102059 A ARP050102059 A AR P050102059A AR P050102059 A ARP050102059 A AR P050102059A AR 049177 A1 AR049177 A1 AR 049177A1
Authority
AR
Argentina
Prior art keywords
polypeptides
conjugates
nucleic acids
interferon
alfa
Prior art date
Application number
ARP050102059A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Maxygen Inc filed Critical Hoffmann La Roche
Publication of AR049177A1 publication Critical patent/AR049177A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Polipéptidos y conjugados de interferon-alfa, y ácidos nucleicos que codifican los polipéptidos. También se incluyen composiciones que comprenden estos polipéptidos, conjugados y ácidos nucleicos; células que contienen o expresan los polipéptidos, los conjugados y los ácidos nucleicos; métodos para preparar los polipéptidos, los conjugados y los ácidos nucleicos; y métodos para usar los polipéptidos, los conjugados y los ácidos nucleicos. Reivindicacion 1: Un polipéptido aislado o recombinante caracterizado porque comprende una secuencia que (a) difiere en entre 1 y 16 posiciones de aminoácidos de SEQ ID No. 1, y (b) comprende una o más sustituciones respecto de SEQ ID No. 1 seleccionadas del grupo que consiste en F48A/L; V51P; F55A; F65A; F68P; L111A; y V114P; donde el polipéptido presenta actividad antiviral.
ARP050102059A 2004-05-19 2005-05-19 Polipeptidos y conjugados de interferon-alfa AR049177A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57250404P 2004-05-19 2004-05-19

Publications (1)

Publication Number Publication Date
AR049177A1 true AR049177A1 (es) 2006-07-05

Family

ID=35428915

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102059A AR049177A1 (es) 2004-05-19 2005-05-19 Polipeptidos y conjugados de interferon-alfa

Country Status (14)

Country Link
US (9) US7318918B2 (es)
EP (1) EP1753779A2 (es)
JP (1) JP2008507298A (es)
CN (1) CN101115769A (es)
AR (1) AR049177A1 (es)
AU (1) AU2005245918A1 (es)
BR (1) BRPI0511196A (es)
CA (1) CA2566247A1 (es)
IL (1) IL178470A0 (es)
MX (1) MXPA06013412A (es)
NO (1) NO20065084L (es)
RU (1) RU2006145020A (es)
TW (1) TW200611910A (es)
WO (1) WO2005113592A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60042730D1 (de) 1999-01-05 2009-09-24 Univ Boston Verbessertes klonierungsverfahren
US20040005673A1 (en) 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
US20030017552A1 (en) * 2000-07-21 2003-01-23 Jarrell Kevin A. Modular vector systems
US7435562B2 (en) 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
EP1759521B1 (en) * 2004-05-12 2016-06-29 Synchronoss Technologies, Inc. Advanced contact identification system
ATE540110T1 (de) 2004-11-11 2012-01-15 Modular Genetics Inc Oligonukleotid-leiterkonstruktion und system zur erzeugung von molekularer vielfalt
US20080124302A1 (en) * 2005-03-09 2008-05-29 Guangwen Wei Uses of Recombinant Super-Compound Interferons
KR20080019619A (ko) 2005-05-18 2008-03-04 맥시겐, 인크. 개량된 인터페론-알파 폴리펩티드
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
US20080014616A1 (en) * 2006-07-11 2008-01-17 Kevin Jarrell Methods of introducing targeted diversity into nucleic acid molecules
US20100009908A1 (en) * 2006-07-25 2010-01-14 Nozomu Nishi Galectin 9-Polymer Conjugates
US7808342B2 (en) * 2006-10-02 2010-10-05 Skyworks Solutions, Inc. Harmonic phase tuning filter for RF switches
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
WO2009006579A1 (en) * 2007-07-05 2009-01-08 Pharmaessentia Corp. Peptide-polymer conjugates
WO2009046080A1 (en) 2007-10-01 2009-04-09 Pharmaessentia Corp. N-terminal modified interferon-alpha
AU2009204998B2 (en) * 2008-01-18 2014-03-27 F. Hoffmann-La Roche Ag Purification of non-glycosylated proteins
US7954022B2 (en) * 2008-01-30 2011-05-31 Alcatel-Lucent Usa Inc. Apparatus and method for controlling dynamic modification of a scan path
AR074357A1 (es) * 2008-11-17 2011-01-12 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. metodo de dialisis in vitro
US8940501B2 (en) 2009-01-30 2015-01-27 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
SG195192A1 (en) 2011-06-02 2013-12-30 Hanmi Science Co Ltd Non-peptidyl polymer-insulin multimer and method for producing the same
WO2013003555A1 (en) 2011-06-28 2013-01-03 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
CN102358897B (zh) * 2011-10-31 2013-02-13 北京三元基因工程有限公司 重组人寡腺苷酸合成酶-1的制备方法
EP3139955B1 (en) 2014-04-30 2024-03-20 President and Fellows of Harvard College Fusion proteins for treating cancer and related methods
ES2630106T3 (es) * 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
IL299759A (en) 2015-12-30 2023-03-01 Genentech Inc Formulations with reduced polysorbate dissolution
DK3411065T3 (da) * 2016-02-05 2021-07-05 Orionis Biosciences BV Clec9a-bindingsmidler
RU2650755C1 (ru) * 2017-05-24 2018-04-17 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С
AU2021210905A1 (en) * 2020-01-24 2022-09-01 Mural Oncology, Inc. Methods of purification

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
ES506955A0 (es) 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
WO1983002461A1 (en) 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPS60152058A (ja) * 1984-01-20 1985-08-10 Toshiba Corp 半導体記憶装置
US4885166A (en) 1985-06-11 1989-12-05 Ciba-Geigy Corporation Hybrid interferons
US4695626A (en) * 1986-07-29 1987-09-22 Pfizer Inc. 1-aza-4,5-dithiabicyclo [4.2.0] oct-2-en-8-one-2 carboxylate esters
DK0553294T3 (da) 1990-10-17 1999-08-23 Amgen Inc Fremstillingen af sammensætninger til behandlingen af celleproliferationssygdomme
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6007805A (en) 1994-03-07 1999-12-28 Imperial College Of Science And Technology Use of interferon subtype alpha-8 (IFN-α8) to treat viral infections of the liver
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
AU751898B2 (en) 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
KR100731826B1 (ko) 1999-01-14 2007-06-22 볼더 바이오테크놀로지 인코퍼레이티드 유리 시스테인 잔기를 함유하는 단백질의 제조 방법
AU3725600A (en) * 1999-03-02 2000-09-21 Maxygen, Inc. Surrogate orphan ligands for orphan receptors
RU2262510C9 (ru) 1999-05-19 2006-04-20 Лексиген Фармасьютикэлс Корп. Слитый белок, обладающий биологической активностью интерферона-альфа, димерный слитый белок, фармацевтическая композиция, их содержащая, молекула днк (варианты) и способ адресования интерферона-альфа в ткани печени
US20040002474A1 (en) 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
CN1451045A (zh) * 1999-10-07 2003-10-22 马克西根公司 IFN－α同系物
JP2003513681A (ja) * 1999-11-12 2003-04-15 マキシゲン・ホールディングス・リミテッド インターフェロンガンマ・コンジュゲート
ES2290142T3 (es) 2000-05-16 2008-02-16 Bolder Biotechnology, Inc. Metodos para replegamiento de proteinas que contiene residuos de cisteina libre.
AU2002223350A1 (en) 2000-12-01 2002-06-11 Eleanor N. Fish Cytokine receptor binding peptides
KR100459105B1 (ko) 2001-02-15 2004-12-03 선바이오(주) 변형된 인터페론-알파 2ａ 및 2ｂ, 그리고 이들과 ＰＥＧ유도체와의 배합체
AU2003293668A1 (en) 2002-11-15 2004-06-15 F. Hoffmann-La Roche Ag Positional isomers of peg ifn alpha 2a
EP1565205A4 (en) 2002-11-18 2006-07-05 Maxygen Inc INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES

Also Published As

Publication number Publication date
BRPI0511196A (pt) 2007-12-04
TW200611910A (en) 2006-04-16
IL178470A0 (en) 2007-02-11
WO2005113592A3 (en) 2006-04-06
US7541436B2 (en) 2009-06-02
US7537755B2 (en) 2009-05-26
NO20065084L (no) 2006-12-01
US20070020734A1 (en) 2007-01-25
US7531324B2 (en) 2009-05-12
AU2005245918A1 (en) 2005-12-01
US7541163B2 (en) 2009-06-02
US7531630B2 (en) 2009-05-12
US20080031853A1 (en) 2008-02-07
US20070225205A1 (en) 2007-09-27
US20070025966A1 (en) 2007-02-01
US7318918B2 (en) 2008-01-15
US20050266465A1 (en) 2005-12-01
EP1753779A2 (en) 2007-02-21
US20080171363A1 (en) 2008-07-17
JP2008507298A (ja) 2008-03-13
RU2006145020A (ru) 2008-06-27
US20080076710A1 (en) 2008-03-27
CN101115769A (zh) 2008-01-30
MXPA06013412A (es) 2007-01-23
US20070020235A1 (en) 2007-01-25
US20070225204A1 (en) 2007-09-27
CA2566247A1 (en) 2005-12-01
WO2005113592A2 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
ATE400656T1 (de) Mini-dystrophin nukleinsäure- und peptidsequenzen
ES2513716T3 (es) Enzimas lecitina-colesteros acitransferasa modificadas
PT1548032E (pt) Péptidos kdr e vacinas que os contêm
MX2024015050A (es) L-asparaginasa modificada
CY1116285T1 (el) Ανασυνδυασμενες ν-γλυκοζυλιωμενες πρωτεϊνες απο προκαρυωτικα κυτταρα
ES2536974T3 (es) Péptidos de epítopos del receptor de EGF y usos de los mismos
ES2721172T3 (es) Una nueva clase de moléculas terapéuticas a base de proteínas
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
ES2531290T3 (es) Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
MX2010004371A (es) Proteasa de streptomyces.
ES2531142T3 (es) Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
CO5700788A2 (es) Composiciones y metodos para inmunoterapia especifica de wt1
ES2691539T3 (es) Luciferasas de Oplophorus sintéticas con mayor emisión de luz
CO6251278A2 (es) Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina -1 y polietilenglicol
NZ580378A (en) Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
AR040446A1 (es) Defensinas de plantas
DK1265914T3 (da) WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
AR059300A1 (es) Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
NO20052363L (no) Interferon-alfa polypeptider og konjugater
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos
AR087719A2 (es) Celula de planta transformada, cultivo de tejidos y planta transgenica
ES2507094T3 (es) Proteína específica del timo
DK1276763T3 (da) Anti-fryseproteiner, deres fremstilling og anvendelse

Legal Events

Date Code Title Description
FB Suspension of granting procedure